(66 days)
Not Found
No
The description details a standard immunoassay method based on turbidimetry and a mathematical function for concentration determination. There is no mention of AI or ML in the device description, intended use, or performance studies.
No
The device is an in vitro diagnostic test intended to quantitatively measure albumin in human urine. It aids in the diagnosis but does not directly provide therapy or treatment.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is "an in vitro diagnostic test intended to quantitatively measure albumin in human urine" and that "Measurement of albumin aids in the diagnosis of kidney and intestinal diseases" and "aids in the diagnosis and treatment of heart diseases or thyroid disorders". It also refers to the Calibrator as an "in vitro diagnostic device."
No
The device is an in vitro diagnostic test involving reagents and a clinical chemistry system, which are hardware components.
Based on the provided text, yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
-
Explicit Statement in Intended Use: The "Intended Use / Indications for Use" section clearly states: "The Dade Behring Dimension® Microalbumin (MALB) Flex® reagent cartridge method is an in vitro diagnostic test intended to quantitatively measure albumin in human urine." and "The Dade Behring Dimension® Microalbumin Calibrator is an in vitro diagnostic device intended for use on Dade Behring Dimension® clinical chemistry systems for medical purposes..."
-
Nature of the Test: The test measures a substance (albumin) in a biological sample (human urine) to aid in the diagnosis and treatment of diseases. This is the core function of an in vitro diagnostic device.
-
Device Description: The description details a laboratory-based method (PETINIA) and a calibrator used in a clinical chemistry system, further supporting its use in a diagnostic laboratory setting.
Therefore, the text explicitly identifies both the reagent cartridge method and the calibrator as in vitro diagnostic devices.
N/A
Intended Use / Indications for Use
The Dade Behring Dimension® Microalbumin (MALB) Flex® reagent cartridge method is an in vitro diagnostic test intended to quantitatively measure albumin in human urine. Measurement of albumin aids in the diagnosis of kidney and intestinal diseases. Measurement also aids in the diagnosis and treatment of heart discases or thyroid disorders which are characterized by proteinuria or albuminuria.
The Dade Behring Dimension® Microalbumin Calibrator is an in vitro diagnostic device intended for use on Dade Behring Dimension® clinical chemistry systems for medical purposes to establish points of reference that are used in the determination of albumin in urine.
Product codes (comma separated list FDA assigned to the subject device)
DCF; JIT
Device Description
Method
The Microalbumin (MALB) method (DF114) is based on a particle-enhanced turbidimetric inhibition immunoassay (PETINIA) adapted to the Dimension® clinical chemistry system which allows direct quantitation of albumin in urine samples. The MALB Flex® reagent cartridge contains a particle reagent (PR) consisting of latex particles with human albumin bound to the surface. Aggregates of these particles are formed when a monoclonal antibody (Ab) to human albumin is introduced. Albumin (ALB) present in the sample competes with the particles for the antibody, thereby decreasing the rate of aggregation. Hence, the rate of aggregation is inversely proportional to the concentration of albumin in the sample. The rate of aggregation is measured using bichromatic turbidimetric reading at 340 and 700 nm. The concentration is determined by means of a mathematical function.
PR + Ab + ALB (sample) → PR-Ab Complex + Ab-ALB (scatters at 340 nm)
Calibrator
The Dade Behring Dimension® Microabumin Calibrator (DC114) is a buffered aqueous product containing weighed-in quantities of human albumin. The calibrator is packaged as a 5-level kit at nominal albumin concentrations of 0, 12.5, 25, 50, and 110 mg/L.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Split-sample comparative performance was evaluated at Dade Behring between the Dimension® MALB Flex® reagent cartridge method assay system and the BN II nephelometric N Antiserum to Human Albumin assay. The results are summarized below:
Comparative Method: N Antiserum to Human Albumin (Dade Behring BN II)
Slope: 0.97
Intercept (mg/L): 0.45
Correlation Coefficient: 0.999
n: 50
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Other commercially available urinary albumin assay systems such as the Dade Behring nephelometric (BN II) N Antiserum to Human Albumin assay (K972929), Dade Behring Urinary Albumin Calibrator (K936201)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.5040 Albumin immunological test system.
(a)
Identification. An albumin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the albumin (a plasma protein) in serum and other body fluids. Measurement of albumin aids in the diagnosis of kidney and intestinal diseases.(b)
Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
0
JAN 1 2 2004
Summary of Safety and Effectiveness Information
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR§807.92.
| Submitter's Name: | Richard M. Vaught
Dade Behring Inc.
P.O. Box 6101
Newark, DE 19714-6101 |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date of Preparation: | November 6, 2003 |
| Name of Product(s): | Dimension® Microalbumin (MALB) Flex® reagent cartridge (DF114)
and
Dimension® Microalbumin Calibrator (DC114) |
| FDA Classification Name(s): | Albumin test system (21CFR§866.5040)
Calibrator (21CFR§862.1150) |
| Predicate Device(s): | Method: Other commercially available urinary albumin assay
systems such as the Dade Behring nephelometric (BN II)
N Antiserum to Human Albumin assay (K972929). |
| | Calibrator: Other commercially available calibrators such as the Dade
Behring Urinary Albumin Calibrator (K936201). |
Device Description(s):
Method
The Microalbumin (MALB) method (DF114) is based on a particle-enhanced turbidimetric inhibition immunoassay (PETINIA) adapted to the Dimension® clinical chemistry system which allows direct quantitation of albumin in urine samples. The MALB Flex® reagent cartridge contains a particle reagent (PR) consisting of latex particles with human albumin bound to the surface. Aggregates of these particles are formed when a monoclonal antibody (Ab) to human albumin is introduced. Albumin (ALB) present in the sample competes with the particles for the antibody, thereby decreasing the rate of aggregation. Hence, the rate of aggregation is inversely proportional to the concentration of albumin in the sample. The rate of aggregation is measured
1
using bichromatic turbidimetric reading at 340 and 700 nm. The concentration is determined by means of a mathematical function.
PR + Ab + ALB (sample) → PR-Ab Complex + Ab-ALB (scatters at 340 nm)
Calibrator
The Dade Behring Dimension® Microabumin Calibrator (DC114) is a buffered aqueous product containing weighed-in quantities of human albumin. The calibrator is packaged as a 5-level kit at nominal albumin concentrations of 0, 12.5, 25, 50, and 110 mg/L.
Intended Use:
Method
The Dade Behring Dimension® Microalbumin (MALB) Flex® reagent cartridge method is an in vitro diagnostic test intended to quantitatively measure albumin in human urine.
Calibrator
The Dade Behring Dimension® Microalbumin Calibrator is an in vitro diagnostic product used to calibrate the Microalbumin (MALB) method on Dade Behring Dimension® clinical chemistry systems.
Comparison to Predicate:
Split-sample comparative performance was evaluated at Dade Behring between the Dimension® MALB Flex® reagent cartridge method assay system and the BN II nephelometric N Antiserum to Human Albumin assay. The results are summarized below:
| Comparative
Method | Slope | Intercept
(mg/L) | Correlation
Coefficient | n |
|------------------------------------------------------|-------|---------------------|----------------------------|----|
| N Antiserum to Human Albumin
(Dade Behring BN II) | 0.97 | 0.45 | 0.999 | 50 |
Comments on Substantial Equivalence:
Both Dade Bchring albumin assay systems - the Dimension® Microalbumin (MALB) Flex® reagent cartridge method and the BN 11 nephelometric N Antiserum to Human Albumin are intended for determination of albumin in urine. Split-sample comparative data demonstrate
rev PAGE 000006 1/5/2004
2
good agreement (correlation) between the methods. Both products utilize light scattering detection techniques for the measurement of albumin.
Conclusion:
The Dade Behring Dimension® Microalbumin (MALB) Flex® reagent cartridge method (DF114) and the Dade Behring BN II nephelometric N Antiserum to Human Albumin assay are substantially equivalent based on their intended purpose, design and the comparison performance results as described carlier. Also, the Dade Behring Dimension® Microalbumin Calibrator (DC114) is substantially equivalent to other calibrators, such as the Dade Behring Urinary Albumin Calibrator based on its design and intended purpose.
Richard M. Vaught Regulatory Affairs and Compliance Manager November 6, 2003
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the bird symbol.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JAN 1 2 2004
Mr. Richard M. Vaught Regulatory Affairs and Compliance Manager Dade Behring Inc. P.O. Box 6101 Newark, DE 19714
Re: K033525
KU33223
Trade/Device Name: Dimension® Microalbumin (MALB) Flex® reagent cartridge (DF114) Dimension® Microalbumin Calibrator (DC114) Regulation Number: 21 CFR 866.5040 Regulation Name: Albumin immunological test system Regulatory Class: Class II Product Code: DCF; JIT Dated: November 6, 2003 Received: November 7, 2003
Dear Mr. Vaught:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The r ou mayy are so provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean I toase of actived a determination that your device complies with other requirements of the Act that I Drideral statutes and regulations administered by other Federal agencies. You must or uny I vith all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
4
Page 2 --
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
Indications For Use Statement
Device Name(s):
Dimension® Microalbumin (MALB) Flex® reagent cartridge (DF114)
Dimension® Microalbumin Calibrator (DC114)
Indications for Usc:
The Dade Behring Dimension® Microalbumin (MALB) Flex® reagent cartridge method is an in vitro diagnostic test intended to quantitatively measure albumin in human urine. Measurement of albumin aids in the diagnosis of kidney and intestinal diseases. Measurement also aids in the diagnosis and treatment of heart discases or thyroid disorders which are characterized by proteinuria or albuminuria.
The Dade Behring Dimension® Microalbumin Calibrator is an in vitro diagnostic device intended for use on Dade Behring Dimension® clinical chemistry systems for medical purposes to establish points of reference that are used in the determination of albumin in urine.
Richard M. Vaught Regulatory Affairs and Compliance Manager
January 5, 2004
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
OR
| Prescription Use | _ |
|---|---|
| (Per 21 CFR 801.109) |
510(k)_
Over-the-counter Use
Division Sign-Off
(Optional format 1-2-96)
Office of In Vitro Diagnostic Device Evaluation and Safety
32515
rev PAGE 000004 1/5/2004